The Novavax vaccine is created using more traditional protein-based technology for vaccine development, unlike the other vaccines currently available in the United States (the Pfizer and Moderna mRNA vaccines and viral-vector Johnson & Johnson vaccine). 

The Novavax vaccine uses a combination of purified coronavirus spike proteins and an immune-boosting stimulant called an adjuvant (common in many vaccines) to strengthen the body’s immune response against COVID-19. Novavax has already been authorized in more than 40 countries and has been granted emergency authorization from the European Union and the World Health Organization.

Updated June 29, 2022

Related FAQS